CUSIP: 64132K102
Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
10,043,919
-
Share change
-
-1,870,116
-
Total reported value
-
$1,909,872
-
Price per share
-
$0.19
-
Number of holders
-
30
-
Value change
-
-$678,604
-
Number of buys
-
11
-
Number of sells
-
18
Quarterly Holders Quick Answers
What is CUSIP 64132K102?
CUSIP 64132K102 identifies NBSE - NEUBASE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2023
-
Previous quarter:
Q3 2022
Recent filing periods for CUSIP 64132K102:
Institutional Holders of NEUBASE THERAPEUTICS INC - COM (NBSE) as of Q4 2022
As of 31 Dec 2022,
NEUBASE THERAPEUTICS INC - COM (NBSE) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,043,919 shares.
The largest 10 holders included
GREENLIGHT CAPITAL INC, Point72 Asset Management, L.P., Decheng Capital Management III (Cayman), LLC, VANGUARD GROUP INC, CARNEGIE MELLON UNIVERSITY, Polar Asset Management Partners Inc., Kestra Advisory Services, LLC, CM Management, LLC, JACOB ASSET MANAGEMENT OF NEW YORK LLC, and PRELUDE CAPITAL MANAGEMENT, LLC.
This page lists
30
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.